210353-53-0 Usage
Description
Gemifloxacin mesylate, also known by its brand name Factive, is a third-generation fluorinated quinolone antibacterial agent. It is the mesylate salt of gemifloxacin, which is a new fluoroquinolone derivative that is active against both Gram-positive and Gram-negative bacteria. Gemifloxacin mesylate is a white to light brown solid with a molecular weight of 485.49 and is considered freely soluble at neutral pH. It has a role as an antimicrobial agent and a topoisomerase IV inhibitor.
Uses
Used in Pharmaceutical Industry:
Gemifloxacin mesylate is used as an antimicrobial agent for the treatment of bacterial respiratory infections. It is particularly effective against Streptococcus pneumoniae, including isolates resistant to b-lactams, macrolides, and ciprofloxacin. It is specifically indicated for treating community-acquired pneumonia (CAP) caused by multi-drug resistant S. pneumoniae and for treating acute bacterial exacerbations of chronic bronchitis (AECB).
Used in Respiratory Infections Treatment:
Gemifloxacin mesylate is used as an oral treatment for bacterial respiratory infections, providing enhanced in vitro activity against various strains of bacteria. The recommended dose of gemifloxacin is 320 mg daily for 5 days for AECB and 320 mg daily for 7 days for CAP.
Used in Drug Resistance Management:
Gemifloxacin mesylate is used as a treatment option for multi-drug resistant S. pneumoniae, helping to manage and combat drug resistance in bacterial infections.
Originator
LG Life Sciences (S. Korea)
Biochem/physiol Actions
Gemifloxacin is a broad-spectrum quinolone antibacterial. Fluoroquinolones stabilize DNA strand breaks created by DNA gyrase and topoisomerase IV by binding to the enzyme-DNA complex generating persistent, covalent enzyme–DNA adducts, inhibiting DNA synthesis. Gemifloxacin is used in the treatment of acute bacterial exacerbation of chronic bronchitis and mild-to-moderate pneumonia. Gemifloxacin has also been found to inhibit migration and invasion of human colon cancer cells.
Check Digit Verification of cas no
The CAS Registry Mumber 210353-53-0 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 2,1,0,3,5 and 3 respectively; the second part has 2 digits, 5 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 210353-53:
(8*2)+(7*1)+(6*0)+(5*3)+(4*5)+(3*3)+(2*5)+(1*3)=80
80 % 10 = 0
So 210353-53-0 is a valid CAS Registry Number.
210353-53-0Relevant articles and documents
NOVEL POLYMORPHS OF GEMIFLOXACIN MESYLATE
-
Page/Page column 16, (2010/12/31)
The present invention provides novel crystalline sesquihydrate form 1, sesquihydrate form 2, anhydrous form 3 and anhydrous form 4 of gemifloxacin mesylate, processes for their preparation and pharmaceutical compositions containing them. The present inven
PROCESS FOR PRODUCTION OF NAPHTHYRIDINE-3-CARBOXYLIC ACID DERIVATIVES
-
Page 6, (2008/06/13)
-
NEW PROCESS FOR PREPARING 4-AMINOMETHYL-3-ALKOXYIMINOPYRROLIDINE METHANESULFONATE
-
Page 17-18, (2008/06/13)
The present invention relates to a process for the preparation of 4-aminomethyl-3-alkoxyiminopyrrolidine methanesulfonate, a key intermediate of quinolone antibiotics. According to the process of the present invention, the total number of steps has been shortened to 2-3 steps, the solid separation is not required, and the use of costly chemicals, particularly (BOC)2O (t-butoxycarbonyl anhydride), several organic solvents and reactants, is eliminated.
